The primary regulatory authority for health products in Czechia is the Státní ústav pro kontrolu léčiv (SÚKL), which operates under the Ministry of Health and oversees the registration, quality control, and post-market surveillance of pharmaceuticals, medical devices, diagnostics, and digital health solutions. The Czech regulatory framework is fully harmonised with European Union law, meaning that pharmaceuticals are governed primarily by Directive 2001/83/EC and Regulation (EC) No 726/2004, while medical devices fall under EU MDR (Regulation 2017/745) and IVD Regulation 2017/746. Products holding a valid EMA centralised marketing authorisation or a mutual recognition/decentralised procedure approval are automatically valid in Czechia, while nationally registered products must go through SÚKL directly. Digital health tools and software as a medical device (SaMD) are assessed in accordance with MDCG guidance and the applicable EU MDR classification rules.
For national submissions, applicants must comply with the Common Technical Document (CTD) format and submit dossiers in Czech or English depending on the procedure type. A local representative or EU-based Responsible Person is mandatory for non-EEA manufacturers. Czechia participates actively in the European Medicines Agency (EMA) network and the Medical Device Coordination Group (MDCG), and SÚKL serves as a reference or concerned member state in numerous EU-wide procedures. Recent reforms include accelerated pathways for orphan medicines and ATMPs introduced in line with the EU Pharmaceutical Strategy for Europe, enhanced pharmacovigilance obligations under GDPR-compliant data frameworks, and the progressive adoption of the European Health Data Space (EHDS) principles into national digital health regulation.
Public procurement of health products in Czechia is primarily coordinated through the Ministry of Health, the State Institute for Drug Control, and individual healthcare institutions including university hospitals and regional health authorities. The public healthcare system is predominantly funded through statutory health insurance, administered by health insurance funds of which the Všeobecná zdravotní pojišťovna (VZP, General Health Insurance Fund) is the largest. Reimbursement and pricing decisions for pharmaceuticals are governed by Act No. 48/1997 Coll. on Public Health Insurance, with SÚKL conducting health technology assessment (HTA)-informed reimbursement reviews. Medical devices and diagnostics are procured through public tender procedures regulated by Act No. 134/2016 Coll. on Public Procurement, which transposes EU Directive 2014/24/EU. Centralised procurement for selected commodities is managed at the national level, while hospitals and regional health entities frequently conduct their own tendering processes, creating a layered, decentralised procurement environment.
The private healthcare sector in Czechia is growing and represents a meaningful procurement channel for premium medical devices, diagnostics, and digital health platforms, operating largely outside the public reimbursement system. Czechia is a high-income EU member state and does not rely on donor-funded procurement mechanisms such as UNICEF Supply Division, the Global Fund, USAID, or Gavi, which are primarily active in low- and middle-income countries. Access to EU structural and cohesion funds, as well as Horizon Europe research and innovation grants, does however influence investment in digital health infrastructure and medical technology modernisation. Czechia does not maintain explicit local manufacturing preference policies in public tenders, as such requirements would conflict with EU single market principles, although national strategic stockpiling initiatives introduced following the COVID-19 pandemic have encouraged greater domestic and regional supply chain resilience for critical health products.
This is a generic market overview. For a structured entry brief tailored to your product category, including regulatory pathway, pricing, and risk assessment, use the Market Brief tool.
Generate a free Market Brief for Czechia →